Search clinical trials for: Insulin Glargine (HOE901) [Lantus]

Total 593 results

Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
University of Pittsburgh
Sanofi

Completed

Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings

Hyperglycemia | Type 2 Diabetes

United States
Emory University
Merck Sharp & Dohme LLC

Completed

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Hyperglycemia | Type 2 Diabetes Mellitus | Hospitalization

United States
Sanofi

Completed

A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus (AT-LANTUS)

Diabetes Mellitus, Type 2
Sanofi

Completed

SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1

Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice

Diabetes Mellitus

Belgium
Sanofi

Completed

32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1
Emory University

Completed

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery (SITACABG NonDM)

Coronary Artery Disease

United States
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, France, Sweden, Poland, Turkey, Korea, Republic of, India, South Africa
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)

Diabetes Mellitus, Type 2

United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Spain, Denmark, Austria, Belgium, Serbia, Germany, Slovenia, Canada, France, Finland, Former Serbia and Montenegro, Czech Republic, Norway
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Insulin Glargine in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Sanofi

Completed

Extension to Study HMR1964A/3011 in Belgium

Diabetes Mellitus

Belgium
Ain Shams University

Recruiting

Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis

Chronic Kidney Diseases

Egypt
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

Denmark
Inova Health Care Services

Withdrawn

The Inova Type 2 Diabetes Mellitus Study (InovaDM2)

Diabetes, Type 2

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Sanofi

Withdrawn

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

Hyperglycemia | Leukemia

United States
Sanofi

Completed

Lantus Versus Levemir Treat-To-Target (L2T3)

Diabetes Mellitus, Type 2

Korea, Republic of, Russian Federation, Spain, Denmark, Canada, Germany, Ireland, Portugal, Australia, India, Turkey, Netherlands, Sweden, United Kingdom, Finland, Switzerland, Romania, Brazil, Serbia, Taiwan
Newcastle University
Sanofi; Medtronic; Newcastle-upon-Tyne Hospitals NHS Trust; Newcastle Primary Care...

Completed

Prevention of Severe Hypoglycemia in Type 1 Diabetes

Type 1 Diabetes Mellitus

United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Novo Nordisk A/S

Completed

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes (EFFICACY)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Argentina, Thailand, India, Korea, Republic of
Northwestern University

Terminated

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Insulin Resistance, Diabetes | Hyperglycemia Steroid-induced

United States
Shenzhen Second People's Hospital

Unknown

Study on the Feasibility of Community Doctors Guided by Specialists to Use Basic Insulin

Type 2 Diabetes
Eli Lilly and Company

Completed

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus (IMAGINE 5)

Diabetes Mellitus, Type 2

United States, Germany, Israel, Czechia, Spain, Russian Federation, Romania, Puerto Rico, Greece
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Diabetes Mellitus, Type 2

United States, Italy, Canada, Germany, Czechia
Novo Nordisk A/S

Completed

Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Germany, United Kingdom, Austria, Belgium, France, Ireland
Sanofi

Completed

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Diabetes Mellitus

United States
Vancouver General Hospital

Terminated

Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia (PTHG)

Post-Transplant Glucocorticoid Induced Diabetes

Canada
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus (EDITION JUNIOR)

Type 1 Diabetes Mellitus

France, Czechia, Chile, Israel, Spain, Hungary, Mexico, Serbia, Japan, Canada, Brazil, Sweden, Denmark, Argentina, United States, Bulgaria, Germany, Italy, Latvia, North Macedonia, Poland, Romania, Russian Federation, United Kingdom
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Diabetes Mellitus, Type 2

India, United States, Thailand, Japan, Germany, Turkey, Hungary, Malaysia, Poland, South Africa, Czechia, Italy, France, Slovenia
Eli Lilly and Company

Completed

A Study for Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Israel
Sanofi

Completed

Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement (SAFIR)

Diabetes Mellitus Type 2
Novo Nordisk A/S

Completed

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Diabetes Care Center

Unknown

A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections

Diabetes Mellitus Type 1

United States
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, France, United Kingdom, Russian Federation, Germany, South Africa
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Spain, Russian Federation, Turkey, Austria, India, Korea, Republic of
Biologics & Biosimilars Collective Intelligence...
Merck Sharp & Dohme LLC; Pfizer; AbbVie; University of Pittsburgh; Boehringer Ingelheim and other collaborators

Completed

Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics

Diabetes
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States

Search clinical trials for: Insulin Glargine (HOE901) [Lantus]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations